Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease
- PMID: 24345989
- DOI: 10.1097/MOL.0000000000000040
Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease
Abstract
Purpose of review: The lipid hypothesis of atherosclerosis is mainly predicated on the function of apolipoprotein (apo)B lipoproteins, which promote atherosclerosis, and apoA lipoproteins, which prevent it. However, accumulating evidence suggests causal roles of other apolipoproteins, abundant surface components of apoB and apoA lipoprotein, in promoting atherosclerosis and other metabolic diseases. This article reviews recent literature on one such apolipoprotein: apoCIII.
Recent findings: Population studies have consistently demonstrated that plasma apoCIII strongly predicts cardiovascular disease. ApoCIII's atherogenicity was traditionally attributed to hypertriglyceridemia because of its inhibition on the lipolysis of triglyceride-rich lipoproteins. Recent evidence expands this function and reveals apoCIII's key role in hepatic assembly and secretion of triglyceride-rich lipoproteins. In addition to these indirect atherogenic functions mediated through dyslipidemia, recent research discovers that apoCIII directly provoke proinflammatory responses in vascular cells, including monocytes and endothelial cells. These direct atherogenic effects are dependent on apoCIII. ApoCIII is also involved in pancreatic beta-cell biology and contributes to type I diabetes.
Summary: Recent data further strengthen the theory that apoCIII exerts strong atherogenic functions through both indirect and direct mechanisms. Encouraging results from early stage clinical trials demonstrate that modulating apoCIII per se is a novel and potent therapeutic approach to managing dyslipidemia and cardiovascular disease risk.
Similar articles
-
Recent Apolipoprotein CIII trials.Curr Opin Lipidol. 2022 Dec 1;33(6):309-318. doi: 10.1097/MOL.0000000000000849. Epub 2022 Sep 28. Curr Opin Lipidol. 2022. PMID: 36206093 Review.
-
ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.Curr Atheroscler Rep. 2017 Nov 9;19(12):62. doi: 10.1007/s11883-017-0697-3. Curr Atheroscler Rep. 2017. PMID: 29124482 Review.
-
ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia.Biochemistry. 2008 Sep 30;47(39):10491-502. doi: 10.1021/bi801249c. Epub 2008 Sep 4. Biochemistry. 2008. PMID: 18767813
-
Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells.Circulation. 2006 Feb 7;113(5):691-700. doi: 10.1161/CIRCULATIONAHA.105.591743. Circulation. 2006. PMID: 16461842
-
Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.J Clin Invest. 1997 Jun 1;99(11):2672-81. doi: 10.1172/JCI119456. J Clin Invest. 1997. PMID: 9169497 Free PMC article.
Cited by
-
A novel mouse model of familial combined hyperlipidemia and atherosclerosis.Acta Pharmacol Sin. 2024 Jun;45(6):1316-1320. doi: 10.1038/s41401-024-01241-8. Epub 2024 Mar 8. Acta Pharmacol Sin. 2024. PMID: 38459255
-
The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease.Eur Cardiol. 2023 Sep 28;18:e56. doi: 10.15420/ecr.2023.16. eCollection 2023. Eur Cardiol. 2023. PMID: 37860700 Free PMC article. Review.
-
Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review.Cardiovasc Diabetol. 2022 Dec 5;21(1):272. doi: 10.1186/s12933-022-01703-5. Cardiovasc Diabetol. 2022. PMID: 36471375 Free PMC article. Review.
-
Interventional hepatic apoC-III knockdown improves atherosclerotic plaque stability and remodeling by triglyceride lowering.JCI Insight. 2022 Jul 8;7(13):e158414. doi: 10.1172/jci.insight.158414. JCI Insight. 2022. PMID: 35653195 Free PMC article.
-
Multi-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans.J Transl Med. 2021 Jan 6;19(1):6. doi: 10.1186/s12967-020-02663-8. J Transl Med. 2021. PMID: 33407555 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous